A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

Simple item page
dc.contributor.authorRustomjee R.
dc.contributor.authorLienhardt C.
dc.contributor.authorKanyok T.
dc.contributor.authorDavies G.R.
dc.contributor.authorLevin J.
dc.contributor.authorMthiyane T.
dc.contributor.authorReddy C.
dc.contributor.authorSturm A.W.
dc.contributor.authorSirgel F.A.
dc.contributor.authorAllen J.
dc.contributor.authorColeman D.J.
dc.contributor.authorFourie B.
dc.contributor.authorMitchison D.A.
dc.contributor.authorBah-Sow O.Y.
dc.contributor.authorDiop H.
dc.contributor.authorFielding K.
dc.contributor.authorGninafon M.
dc.contributor.authorMitchison D.
dc.contributor.authorLienhardt C.
dc.contributor.authorOdhiambo J.
dc.contributor.authorPerronne C.
dc.contributor.authorPortaels F.
dc.contributor.authorRustomjee R.
dc.contributor.authorRamjee A.
dc.contributor.authorMaster I.
dc.contributor.authorOlowolagba A.
dc.contributor.authorChinappa T.
dc.contributor.authorOsburne G.
dc.contributor.authorBamber S.
dc.contributor.authorPala A.S.
dc.contributor.authorPillay L.
dc.contributor.authorTembe C.
dc.contributor.authorMpangase P.
dc.contributor.authorHadebe T.
dc.contributor.authorNgcobo C.P.
dc.contributor.authorMkhize Z.
dc.contributor.authorDlamini C.N.
dc.contributor.authorGill L.
dc.contributor.authorDube T.
dc.contributor.authorSaul M.
dc.contributor.authorMerle C.
dc.contributor.authorSuma K.F.
dc.date.accessioned2011-05-15T15:53:48Z
dc.date.available2011-05-15T15:53:48Z
dc.date.issued2008
dc.description.abstractSETTING: Current treatment for pulmonary tuberculosis (TB) might be shortened by the incorporation of fluoroquinolones (FQs). OBJECTIVES: A Phase II study aimed to assess the sterilising activities of three novel regimens containing FQs before a Phase III trial of a 4-month regimen containing gatifloxacin (GFX). DESIGN: A total of 217 newly diagnosed smear-positive patients were randomly allocated to one of four regimens: isoniazid (INH), pyrazinamide and rifampicin (RMP) with either ethambutol, GFX, moxifloxacin (MFX) or ofloxacin (OFX) for 2 months. At the end of the study, RMP and INH were given for 4 months. The rates of elimination of Mycobacterium tuberculosis were compared in the regimens using non-linear mixed effects modelling of the serial sputum colony counts (SSCC) during the first 8 weeks. RESULTS: After adjustment for covariates, MFX substitution appeared superior during the early phase of a biexponential fall in colony counts, but significant and similar acceleration of bacillary elimination during the late phase occurred with both GFX and MFX (P = 0.002). Substitution of OFX had no effect. These findings were supported by estimates of time to conversion, using Cox regression, but there were no significant differences in proportions culture-negative at 8 weeks. CONCLUSIONS: GFX and MFX improve the sterilising activity of regimens and might shorten treatment; their progression into Phase III trials therefore seems warranted. © 2008 The Union.
dc.description.versionArticle
dc.identifier.citationInternational Journal of Tuberculosis and Lung Disease
dc.identifier.citation12
dc.identifier.citation2
dc.identifier.issn10273719
dc.identifier.urihttp://hdl.handle.net/10019.1/8823
dc.titleA phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications